Related Experiment Videos
Midazolam attenuates adenosine diphosphate-induced P-selectin expression and platelet-leucocyte aggregation
1Department of Surgery Taipei, Tri-Service General Hospital, Taiwan, ROC.
European Journal of Anaesthesiology
|February 19, 2005
Summary
Midazolam, a sedative, was found to reduce platelet activation markers, specifically P-selectin expression and platelet-leukocyte aggregation. This effect was dose-dependent, suggesting a potential role in managing thrombotic and inflammatory conditions.
Area of Science:
- Hematology
- Pharmacology
- Immunology
Background:
- Platelet activation, indicated by P-selectin expression and platelet-leukocyte aggregation, is crucial in thrombotic and inflammatory diseases.
- Midazolam, a common sedative, is known to affect platelet aggregation and leukocyte responses, but its impact on platelet-leukocyte adhesion is unclear.
Purpose of the Study:
- To investigate the effect of midazolam on adenosine diphosphate (ADP)-induced P-selectin expression on platelets.
- To examine midazolam's influence on platelet-leukocyte aggregate formation in whole blood.
Main Methods:
- Human whole blood was stimulated with ADP in the presence of varying concentrations of midazolam.
- Flow cytometry was used to analyze platelet P-selectin (CD62P) expression and platelet-leukocyte aggregates (CD45+/CD62P+).
- Leukocyte subpopulations (neutrophils, monocytes, lymphocytes) were identified and analyzed.
Main Results:
- Midazolam significantly inhibited ADP-induced platelet P-selectin expression in a dose-dependent manner.
- Midazolam attenuated platelet-leukocyte aggregation, primarily involving neutrophils and monocytes.
- Maximum inhibition was observed at a midazolam concentration of 3 x 10(-4)M (P < 0.01).
Conclusions:
- Midazolam effectively reduces ADP-induced platelet surface P-selectin expression.
- Midazolam decreases platelet-leukocyte aggregation, indicating an anti-adhesive effect on activated platelets.